Vrije Universiteit Brussel, Research group Cellular & Molecular Immunology, Pleinlaan 2, 1050 Brussels, Belgium.
Nanomedicine (Lond). 2013 Jun;8(6):1013-26. doi: 10.2217/nnm.13.86.
Nanobodies are recombinant, antigen-specific, single-domain, variable fragments of camelid heavy chain-only antibodies. The innate supremacy of nanobodies as a renewable source of affinity reagents, together with their high production yield in a broad variety of expression systems, minimal size, great stability, reversible refolding and outstanding solubility in aqueous solutions, and ability to specifically recognize unique epitopes with subnanomolar affinity, have combined to make them a useful class of biomolecules for research and various medical diagnostic and therapeutic applications. This article speculates on a number of technological innovations that might be introduced in the nanobody identification platform to streamline the generation of more potent nanobodies and to expand their application range.
纳米抗体是骆驼重链抗体仅有的、重组的、抗原特异性的、单域、可变片段。纳米抗体作为一种可再生的亲和试剂来源,具有先天优势,加上它们在多种表达系统中具有高产量、较小的尺寸、高稳定性、可反复折叠和出色的水溶性,以及能够特异性识别具有亚纳摩尔亲和力的独特表位,这些特性使它们成为一类有用的生物分子,可用于研究和各种医学诊断和治疗应用。本文推测在纳米抗体鉴定平台中可能引入一些技术创新,以简化更有效纳米抗体的生成,并扩大其应用范围。